LKY-047，是 Decursin 的一种衍生物，是一种有效的选择性的可逆竞争性的细胞色素 P45022J2 (CYP2J2) 抑制剂，IC₅₀ 为 1.7 μM。LKY-047 对其他人类 P450 无效，例如 CYP1A2、CYP2A6、CYP2B6、CYP2C8、CYP2C9、CYP2C19、CYP2D6、CYP2E1 和 CYP3A。

LKY-047, a Decursin derivative, is a potent and selective reversible competitive cytochrome P45022J2 (CYP2J2) inhibitor with an IC 50 of 1.7 μM. LKY-047 is inactive against other human P450s, such as CYPs 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A.

Solid

CYP2J2 1.7 μM (IC50)

LKY-047 is a strong competitive inhibitor of CYP2J2-mediated astemizole O-demethylase and terfenadine hydroxylase activity, with Ki values of 0.96 μM and 2.61 μM, respectively. LKY-047 also acted as an uncompetitive inhibitor of CYP2J2-mediated ebastine hydroxylation with a Ki value of 3.61 μM.
At 20 μM LKY-047 concentration, approximately 20-fold greater than the Ki value, LKY-047 is found to inhibit CYP2J2 by 85.3%, and only slightly affecting the enzyme activities of the other P450s tested. LKY-047 weakly inhibits CYP2D6 enzyme activity (37.2%) at 20 μM concentration. has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. Nguyen Minh Phuc, et al. LKY-047: First Selective Inhibitor of Cytochrome P450 2J2. Drug Metab Dispos. 2017 Jul;45(7):765-769.

In Vitro: DMSO : 16.67 mg/mL (39.56 mM; ultrasonic and warming and heat to 60°C)配制储备液